公开(公告)号：UA100513C2

公开(公告)日：2013-01-10

申请号：UAA200910650

申请日：2008-03-21

Applicant: BIOGEN IDEC INC ,  UCB PHARMA SA

Inventor： BURKLY LINDA ,  FERRANT-ORGETTAS JANINE L ,  GARBER ELLEN A ,  HSU YEN-MING ,  SU LIHE ,  TAYLOR FREDERICH R ,  ADAMS RALPH ,  BROWN DEREK THOMAS ,  POPPLEWELL ANDREW GEORGE ,  ROBINSON MARTYN KIM ,  SHOK ANTHONY ,  TYSON KERRY LOUISE

IPC: C07K16/28 ,  A61K39/395 ,  A61P37/00 ,  C12N15/13 ,  C12P21/08

Abstract: Изобретениеотноситсяк CD 154-связывающемубелку (антитела), молекуленуклеиновойкислоты, котораяегокодирует, вектору, клетке-хозяину, способуполученияантитела, композициии применениюданногобелкав приготовлениилекарственногосредствадлялеченияилипрофилактикисостояния, нарушенияилизаболеваниячеловека, опосредствованногов целомиличастичносигнальнымпутемприучастии CD40.

公开(公告)号：CA2791930A1

公开(公告)日：2011-09-15

申请号：CA2791930

申请日：2011-03-09

Applicant: UCB PHARMA SA

Inventor： TYSON KERRY LOUISE

IPC: C07K16/28 ,  C07K14/705 ,  C07K16/46 ,  C12N15/13

Abstract: A humanised agonistic antibody which binds human PD-1 comprising a heavy chain wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID N0:1 for CDR-H1, the sequence given in SEQ ID NO : 2 for CDR-H2 and the sequence given in SEQ ID NO: 3 for CDR-H3 and the heavy chain framework region is derived from human sub-group sequence VH4 3-1 4-30.4 + JH4 (SEQ ID NO: 33). The disclosure also extends to therapeutic uses of the antibody molecules, compositions and methods for producing said antibody molecules.

公开(公告)号：AR075849A1

公开(公告)日：2011-05-04

申请号：ARP100100720

申请日：2010-03-10

Applicant: UCB PHARMA SA

Inventor： PALFRAMAN ROGER THOMAS ,  SMITH BRYAN JOHN ,  LAWSON ALASTAIR DAVID GRIFFITHS ,  GOZZARD NEIL ,  LIGHTWOOD DANIEL JOHN ,  TYSON KERRY LOUISE

IPC: C07K16/24 ,  C12N15/24 ,  C12P21/08 ,  A61K39/395 ,  A61P11/06

Abstract: Una secuencia de ADN dada que la codifica, un vector de clonacion, una célula hospedante, método para producir dichas moléculas de anticuerpos y una composicion farmacéutica que comprende el anticuerpo. Reivindicacion 1: Un anticuerpo antagonista que se une a IL-13 humana, caracterizado porque comprende una cadena pesada, en el que el dominio variable de la cadena pesada comprende al menos una de una CDR que tiene la secuencia dada en SEQ ID Ns:1 para CDR-H1, una CDR que tiene la secuencia dada en SEQ ID Ns:2 para CDR-H2, y una CDR que tiene la secuencia dada en SEQ ID Ns:3 para CDR-H3.

公开(公告)号：UY32489A

公开(公告)日：2010-10-29

申请号：UY32489

申请日：2010-03-11

Applicant: UCB PHARMA SA

Inventor： NEIL GOZZARD ,  LAWSON ALASTAIR DAVID GRIFFITHS ,  LIGHTWOOD DANIEL JOHN ,  PALFRAMAN ROGER THOMAS ,  SMITH BRYAN JOHN ,  TYSON KERRY LOUISE

IPC: A61K39/395 ,  A61P43/00 ,  C07K16/00 ,  C07K16/24 ,  C12N15/79

Abstract: La invención se refiere a moléculas de anticuerpo que tienen especificidad por determinantes antigénicos de IL-13 humana, a usos terapéuticos de las moléculas de anticuerpo, y a métodos para producir dichas moléculas de anticuerpo

公开(公告)号：CA2681530A1

公开(公告)日：2008-10-02

申请号：CA2681530

申请日：2008-03-21

Applicant: BIOGEN IDEC INC ,  UCB PHARMA SA

Inventor： TAYLOR FREDERICK R ,  BURKLY LINDA C ,  BROWN DEREK THOMAS ,  ADAMS RALPH ,  TYSON KERRY LOUISE ,  POPPLEWELL ANDREW GEORGE ,  ROBINSON MARTYN KIM ,  SHOCK ANTHONY ,  SU LIHE ,  HSU YEN-MING ,  FERRANT-ORGETTAS JANINE L ,  GARBER ELLEN A

IPC: C07K16/28 ,  A61K39/395 ,  C12N15/13 ,  C12N15/63

Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) p rotein. This invention also provides a chimeric, humanized or fully human an tibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy cha in sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding protein s of this invention may elicit reduced effector function relative to a secon d anti-CD154 antibody. CD154 binding proteins of this invention are useful i n diagnostic and therapeutic methods, such as in the treatment and preventio n of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.

公开(公告)号：CA2656047A1

公开(公告)日：2008-01-10

申请号：CA2656047

申请日：2007-06-26

Applicant: UCB PHARMA SA

Inventor： POPPLEWELL ANDREW GEORGE ,  LAWSON ALASTAIR DAVID GRIFFITHS ,  ADAMS RALPH ,  TYSON KERRY LOUISE

IPC: C07K16/46

Abstract: The present invention relates to improved methods for the selection of ap propriate human acceptor framework regions for non-human (donor) antibodies and methods for obtaining humanized antibodies of high affinity using such a cceptor frameworks.

公开(公告)号：UA118954C2

公开(公告)日：2019-04-10

申请号：UAA201413210

申请日：2013-05-13

Applicant: UCB PHARMA SA

Inventor： FINNEY HELENE MARGARET ,  LAWSON ALASTAIR DAVID GRIFFITHS ,  SHAW STEVAN GRAHAM ,  SMITH BRYAN JOHM ,  TYSON KERRY LOUISE ,  KEVORKIAN LARA ,  MEIER CHRISTOPH ,  SARKAR KAUSHIK ,  ATHERFOLD PAUL ALAN

IPC: C07K16/28 ,  A61K39/395 ,  A61P17/00 ,  C07K14/00 ,  G01N33/531

Abstract: Винахідстосуєтьсяанти-FcRn антитіла, абойогозв'язуючогофрагмента, аналізудлятестуванняздатностізазначеногоантитілаблокуватиактивність FcRn людини, виділеноїпослідовностіДНК, вектораклонуванняабоекспресії, клітини-хазяїна, способуотриманнятакогоантитіла, фармацевтичноїкомпозиції, способулікуванняпацієнтавідаутоімуннихзахворювань, опосередкованих FcRn.

公开(公告)号：CA2681530C

公开(公告)日：2017-03-28

申请号：CA2681530

申请日：2008-03-21

Applicant: BIOGEN IDEC INC ,  UCB PHARMA SA

Inventor： BURKLY LINDA C ,  FERRANT-ORGETTAS JANINE L ,  GARBER ELLEN A ,  HSU YEN-MING ,  SU LIHE ,  TAYLOR FREDERICK R ,  ADAMS RALPH ,  BROWN DEREK THOMAS ,  POPPLEWELL ANDREW GEORGE ,  ROBINSON MARTYN KIM ,  SHOCK ANTHONY ,  TYSON KERRY LOUISE

IPC: C12N15/13 ,  A61K39/395 ,  C07K16/28 ,  C12N15/63

Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody.

公开(公告)号：BRPI1009576A2

公开(公告)日：2016-03-08

申请号：BRPI1009576

申请日：2010-03-10

Applicant: UCB PHARMA SA

Inventor： LAWSON ALASTAIR DAVID GRIFFITHS ,  SMITH BRYAN JOHN ,  LIGHTWOOD DANIEL JOHN ,  TYSON KERRY LOUISE ,  GOZZARD NEIL ,  PALFRAMAN ROGER THOMAS

IPC: A61K39/395 ,  A61P11/06 ,  C07K16/24 ,  C07K16/46 ,  C12N15/13

公开(公告)号：BRPI0809042A2

公开(公告)日：2014-09-16

申请号：BRPI0809042

申请日：2008-03-21

Applicant: BIOGEN IDEC INC ,  UCB PHARMA SA

Inventor： BURKLY LINDA C ,  FERRANT-ORGETTAS JANINE L ,  GARBER ELLEN A ,  HSU YEN-MING ,  SU LIHE ,  TAYLOR FREDERICK R ,  ADAMS RALPH ,  BROWN DEREK THOMAS ,  POPPLEWELL ANDREW GEORGE ,  ROBINSON MARTYN KIM ,  SHOCK ANTHONY ,  TYSON KERRY LOUISE

IPC: C07K16/28 ,  A61K39/395 ,  C12N15/13 ,  C12N15/63

Abstract: This invention provides binding proteins, including antibodies, antibody derivates and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivate or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.